Xtl Biopharmaceuticals (XTLB) Operating Expenses (2009 - 2024)
Xtl Biopharmaceuticals (XTLB) posted quarterly Operating Expenses of $347000.0 for Q4 2024, up 273.5% year-on-year from $92905.0 in Q1 2024, and up 165.97% on a QoQ basis from -$526000.0 in Q3 2024.
Xtl Biopharmaceuticals (XTLB) Operating Expenses (2009 - 2024) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Operating Expenses for 16 consecutive years, with $347000.0 the latest figure, recorded in Q4 2024.
- Quarterly Operating Expenses rose 273.5% year-over-year to $347000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2025 was -$179000.0 (up 76.9% YoY) and the FY2025 annual result came in at -$1.5 million, down 89.03% from the prior year.
- Operating Expenses climbed to $347000.0 in Q4 2024 per XTLB's latest filing, from -$526000.0 in the prior quarter.
- Over the last five years, Operating Expenses for XTLB reached as high as $1.7 million in Q4 2021 and fell as low as -$526000.0 in Q3 2024.
- A 5-year average of $64750.0 and a median of -$201000.0 in 2022 frame the typical range for Operating Expenses.
- The largest YoY upside for Operating Expenses was 273.5% in 2024 against a maximum downside of 186.75% in 2024.
- Year by year, Operating Expenses stood at $1.6 million in 2020, then grew by 8.88% to $1.7 million in 2021, then retreated by 11.17% to $1.5 million in 2022, then tumbled by 113.03% to -$200000.0 in 2023, then soared by 273.5% to $347000.0 in 2024.
- According to Business Quant data, Operating Expenses over the past three periods registered $347000.0, -$526000.0, and -$433000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -28.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.10 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.78 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.85 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 2.89 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 445.22 Mn |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 347,000.00 |
| Sep 30, 2024 | -526,000.00 |
| Jun 30, 2024 | -433,000.00 |
| Mar 31, 2024 | -163,000.00 |
| Dec 31, 2023 | -200,000.00 |
| Sep 30, 2023 | -189,000.00 |
| Jun 30, 2023 | -151,000.00 |
| Mar 31, 2023 | -225,000.00 |
| Dec 31, 2022 | 1.54 Mn |
| Sep 30, 2022 | -246,000.00 |
| Jun 30, 2022 | -202,000.00 |
| Mar 31, 2022 | -237,000.00 |
| Dec 31, 2021 | 1.73 Mn |
| Sep 30, 2021 | -198,000.00 |
| Jun 30, 2021 | -291,000.00 |
| Mar 31, 2021 | -208,000.00 |
| Dec 31, 2020 | 1.59 Mn |
| Sep 30, 2020 | -165,000.00 |
| Jun 30, 2020 | -217,000.00 |
| Mar 31, 2020 | -251,000.00 |